EGFR and non-small cell lung carcinoma: The RADIANT trial was a randomized phase three trial, including patients with NSCLC stage IB to IIIA expressing EGFR positivity by immunohistochemistry (IHC) or EGFR amplification by fluorescence in situ hybridization (FISH).